Sei Investments Co. raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 203.2% during the 1st quarter, HoldingsChannel reports. The fund owned 1,239,001 shares of the medical research company’s stock after acquiring an additional 830,341 shares during the quarter. Sei Investments Co.’s holdings in Edwards Lifesciences were worth $99,217,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently modified their holdings of the company. Norges Bank bought a new position in Edwards Lifesciences in the 4th quarter worth $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares in the last quarter. Viking Global Investors LP bought a new stake in Edwards Lifesciences during the third quarter valued at about $238,688,000. Marshall Wace LLP grew its holdings in Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after purchasing an additional 2,359,128 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in Edwards Lifesciences by 221.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,060,891 shares of the medical research company’s stock valued at $167,468,000 after purchasing an additional 1,419,022 shares during the period. Institutional investors own 79.46% of the company’s stock.
Edwards Lifesciences Stock Performance
NYSE EW opened at $83.63 on Friday. The stock has a market capitalization of $48.15 billion, a PE ratio of 44.48, a P/E/G ratio of 2.12 and a beta of 0.86. The business has a 50 day simple moving average of $87.70 and a two-hundred day simple moving average of $83.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29.
Insider Buying and Selling
In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,671,117.80. The trade was a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 45,577 shares of company stock worth $3,855,527. Insiders own 0.31% of the company’s stock.
Key Stories Impacting Edwards Lifesciences
Here are the key news stories impacting Edwards Lifesciences this week:
- Positive Sentiment: Q2 sales increased 13.6% year over year to $1.74 billion, topping estimates, while adjusted EPS of $0.78 also beat consensus. Edwards Lifesciences Reports Second Quarter Results
- Positive Sentiment: Management raised its 2026 sales outlook to $6.6 billion-$6.9 billion from $6.5 billion-$6.9 billion, signaling confidence in continued growth. Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth
- Positive Sentiment: TAVR sales rose 11.3% to about $1.26 billion, showing ongoing strength in the company’s largest franchise and supporting the stock move higher. Edwards Lifesciences beats quarterly estimates on strong demand for heart devices
- Neutral Sentiment: The company also guided Q3 revenue and EPS near Street expectations, which was reassuring but not a major additional catalyst. Edwards Lifesciences Reports Second Quarter Results
Analyst Ratings Changes
Several research firms have recently commented on EW. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Robert W. Baird increased their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Citigroup raised their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Finally, Mizuho lifted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $98.95.
Check Out Our Latest Stock Report on Edwards Lifesciences
Edwards Lifesciences Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
